Publication: 2158

Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)

Citation:: J Clin Oncol vol 33 (1) 13-21

Year:: 2015
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pmc-release

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:: 4

Parents:: 342 1001
Children:: None

Program:: OGC
Primary Committee:: Breast
Sec. Committees:

Pharmas:
Grants:: U10CA180821, U10CA180882, CA33601, CA076001, U10 CA180821, P30 CA016086, P50 CA058223, U10 CA180791, CA46368, CA32102, U10 CA180882, U10 CA180867, U10 CA180838, U10 CA180888, CA025224, CA31946

Corr. Author:
Authors:: William M. Sikov Donald A. Berry Charles M. Perou Baljit Singh Constance T. Cirrincione Sara M. Tolaney Charles S. Kuzma Timothy J. Pluard George Somlo Elisa R. Port Mehra Golshan Jennifer R. Bellon Deborah Collyar Olwen M. Hahn Lisa A. Carey Clifford A. Hudis Eric P. Winer

Networks:: CA043, LAPS-CT018, LAPS-IL057, LAPS-MA036, LAPS-MO011, LAPS-NC007, LAPS-NY016, NY021, RI005, SCOR

Study: CALGB-40603
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords:: Bc5, ORIGINAL REPORTS, Rapid Communications